A Phase I, Pharmacokinetics, Safety and Tolerability Study of Single and Multiple Oral Doses of Safinamide in Healthy Adult Chinese Volunteers
Latest Information Update: 20 Mar 2023
At a glance
- Drugs Safinamide (Primary)
- Indications Drug-induced dyskinesia; Multiple system atrophy; Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Zambon SpA
- 24 Aug 2021 Status changed from recruiting to completed.
- 06 Jul 2021 Status changed from not yet recruiting to recruiting.
- 21 Jun 2021 Planned End Date changed from 14 Jul 2021 to 12 Aug 2021.